AURORA study enters its second phase, focusing on specific metastatic breast cancer patient subgroups

Woman in beige jumper looking at the camera

Share This Post

In a significant step towards comprehending and addressing metastatic breast cancer, AURORA has just entered its second phase by commencing the recruitment of patients for the extension of this academic research programme. This new phase will have a specific focus on breast cancer patient subgroups where there is high clinical unmet need and rapidly evolving research, including triple-negative breast cancer, invasive lobular carcinoma, and late relapse cases. A total of 252 patients will be included and closely monitored for up to five years.

Collaborative effort and global significance

This second phase of AURORA is a collaborative initiative involving 17 hospitals from seven BIG research groups across eight European countries. This collaborative effort represents a pivotal moment for the global pursuit of knowledge about metastatic breast cancer at a time of rapid changes and financial challenges in cancer research.

Impactful publications

The Core Data Analysis Committee, comprising bioinformaticians and clinical experts within the AURORA program, is driving progress in data generation from 1156 patients already included in the first part of the study that started in 2014. Fast forward to 2023, various AURORA publications have analysed different aspects of metastatic breast cancer. The annual San Antonio Breast Cancer Symposium in December 2023 will feature a poster spotlight discussion on the analysis of patients in AURORA with ER+/HER2- breast cancer and its impact on decisions for first-line systemic treatment. The second  manuscript, including data from all 1156 patients from the first phase, is scheduled for publication in 2024.

HOPE for patients through global collaboration

AURORA’s significance extends beyond scientific exploration, serving as a beacon of hope for patients living with metastatic breast cancer and researchers worldwide. The joint efforts of many partners (Institut Jules Bordet, Frontier Science Scotland, BIG member groups, the NCI National Clinical Trials Network), the support of the programme’s main funder, the Breast Cancer Research Foundation, and the engagement of patients, underscore the power of unified action to improve our understanding of this difficult disease. The start of the AURORA extension brings us one step closer to potentially saving numerous lives.

More to explore

The Queen of the Belgians, Martine Piccart and David Cameron

A round table with Her Majesty

On Thursday 29 September, the Breast International Group had the honour of hosting its Honorary President, Her Royal Highness the Queen of the Belgians, around a round table session with over 40 influential people from the Belgian Business world.